EGFR Positive Non-small Cell Lung Cancer

Showing NaN - NaN of 2

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

Active, not recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Hong Kong, Hong Kong
  • +8 more
Jan 10, 2023

Osimertinib for Advanced EGFR-positive NSCLC Patients

Recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Non Small Cell Lung Cancer
    • Singapore, Singapore
      National University Hospital
    Aug 31, 2021